BEGIN:VCALENDAR VERSION:2.0 PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.41.90// CALSCALE:GREGORIAN UID:32316463-6138-4434-b937-336262626162 BEGIN:VEVENT UID:223e05d2ef11b5e635f4cf192cce73bfb229f18e@swoogo.com DTSTAMP:20260905T015459Z DESCRIPTION:Migraine is more than just a headache. It is a chronic\, often disabling neurological disease and a significant source of lost productivi ty\, reduced quality of life\, and rising medical costs\, especially withi n the federal health system. The objective of the session is to provide pa rticipants with practical insights into integrating migraine treatment wit hin federal medicine\, with the goal of impacting migraine care and improv ing patient outcomes. Attendees will gain an understanding of how targeted therapies can provide hope for people living with migraine who have previ ously faced limited treatment options and frequent debilitating attacks. T his program will explore the substantial burden of migraine among individu als served by federal medicine\, highlighting the unmet needs in this popu lation. The session will focus on: 1. The evolution of migraine treatment landscape from the use of traditional\, non-migraine specific medications to targeted therapies that are part of today’s approach to migraine manage ment. 2. A focused review of Phase 3 clinical data supporting Abbvie's mig raine treatments. 3. Recent real-world data highlighting patient-centered outcomes for Abbvie products. DTSTART:20260304T181500Z DTEND:20260304T191500Z LAST-MODIFIED:20260905T015459Z LOCATION: SEQUENCE:0 STATUS:CONFIRMED SUMMARY:How Therapies and Federal Medicine Are Transforming Migraine Care TRANSP:OPAQUE X-ALT-DESC;FMTTYPE=text/html:

Migraine is more than just a headache. It i s a chronic\, often disabling neurological disease and a significant sourc e of lost productivity\, reduced quality of life\, and rising medical cost s\, especially within the federal health system. The objective of the sess ion is to provide participants with practical insights into integrating mi graine treatment within federal medicine\, with the goal of impacting migr aine care and improving patient outcomes. Attendees will gain an understan ding of how targeted therapies can provide hope for people living with mig raine who have previously faced limited treatment options and frequent deb ilitating attacks. This program will explore the substantial burden of mig raine among individuals served by federal medicine\, highlighting the unme t needs in this population. The session will focus on: 1. The evolution of migraine treatment landscape from the use of traditional\, non-migraine s pecific medications to targeted therapies that are part of today’s approac h to migraine management. 2. A focused review of Phase 3 clinical data sup porting Abbvie's migraine treatments. 3. Recent real-world data highlighti ng patient-centered outcomes for Abbvie products.

BEGIN:VALARM UID:63646337-3531-4231-b333-303965323763 ACTION:DISPLAY DESCRIPTION:Migraine is more than just a headache. It is a chronic\, often disabling neurological disease and a significant source of lost productivi ty\, reduced quality of life\, and rising medical costs\, especially withi n the federal health system. The objective of the session is to provide pa rticipants with practical insights into integrating migraine treatment wit hin federal medicine\, with the goal of impacting migraine care and improv ing patient outcomes. Attendees will gain an understanding of how targeted therapies can provide hope for people living with migraine who have previ ously faced limited treatment options and frequent debilitating attacks. T his program will explore the substantial burden of migraine among individu als served by federal medicine\, highlighting the unmet needs in this popu lation. The session will focus on: 1. The evolution of migraine treatment landscape from the use of traditional\, non-migraine specific medications to targeted therapies that are part of today’s approach to migraine manage ment. 2. A focused review of Phase 3 clinical data supporting Abbvie's mig raine treatments. 3. Recent real-world data highlighting patient-centered outcomes for Abbvie products. TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR